Wird geladen...
Adjuvant Trastuzumab: Does Time Really Matter?
Trastuzumab is now the standard of care for metastatic and early breast cancer; however, questions remain regarding the optimal schedule of trastuzumab in the adjuvant setting. This commentary discusses the results from recent clinical trials with regard to the optimal duration of trastuzumab treatm...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
AlphaMed Press
2013
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3662838/ https://ncbi.nlm.nih.gov/pubmed/23624497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0094 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|